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Abstract
Fanconi syndrome is a metabolic disorder involving dysfunction of the renal proximal tubules, resulting in excessive urinary excre-
tion of several metabolites. Various factors may lead to Fanconi syndrome, as it may be a genetic disease with primary or secondary
etiologies, or may be acquired. In this study, we report a unique case of Fanconi syndrome with development of a relatively rare
acute leukemia, a condition that has not been reported before. The case was an 8-year-old boy with familial occurrence of Fanconi
syndrome, presenting with pallor, asthenia, recurrent infections, growth failure, and a variety of biochemical and hematological
abnormalities. After physical examination, radiographic studies, and comprehensive laboratory analyses, Fanconi syndrome asso-
ciated with bilineal acute leukemia, of myeloid and T-lymphoid lineages, was diagnosed.
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1. Background
Fanconi syndrome (FS) is a rare metabolic disease iden-
tified by dysfunction of the renal proximal tubules. The
low reabsorption capacity of the proximal tubules re-
sults in the abnormal urinary excretion of several metabo-
lites, including phosphate, glucose, amino acids, uric acid,
and various ions. Other biochemical findings include hy-
pokalemia, hypouricemia, and metabolic acidosis (1, 2).
This syndrome is highly associated with osteomalacia, os-
teoporosis, muscle weakness, and severe bone pain. The
production of monoclonal light chains, especially kappa
chains, which have toxic effects on the renal tubules, is also
reported in these patients (3).
FS may be a genetic disease with primary or secondary
causes, or may be acquired. A missense mutation in
sodium phosphate cotransporter (NaPi-II) of the proximal
tubular apical membrane accounts for primary FS. This
syndrome may also develop secondary to systemic disease.
The genetic and acquired causes of FS are indicated in Table
1. The causes of FS may also lead to renal tubular acidosis.
Light-chain-associated FS is the most frequent among the
acquired factors (4).
Dysglobulinemia is a feature of FS, and some studies in
the literature report FS in association with myeloma, amy-
loidosis, and Bence-Jones proteinuria (5). In this study, we
report a unique case of FS that was complicated by bilineal
acute leukemia with myeloid and T-lymphoid lineages.
2. Case Presentation
An 8-year-old boy was admitted to our center com-
plaining of pallor, anemia, asthenia, and recurrent infec-
tions in January 2014. The patient was the first child of
a family with three children. Physical examination re-
vealed severe growth failure, with a weight of 12 kg weight,
height of 97 cm, and head circumference of 46 cm. Hep-
atosplenomegaly was observed with a palpable liver and
spleen 3 cm and 2 cm below the costal margin, respec-
tively. On abdominal ultrasound, the sizes of the liver and
spleen were 95 mm and 86 × 40 mm, respectively, and
an echogenic focus in the left kidney was also detected.
The patient presented with genu valgum and was not able
to walk easily. Bilateral cataracts and lens opacity were
found, with 6/10 and 7/10 visual acuity for the right and
left eyes, respectively. Wrist radiography showed widen-
ing, fraying, and cupping, all suggestive of rickets, and
bone age was 3.5 years. Complete blood count (Sysmex KX
21N, Japan) demonstrated a white blood cell count of 4.2×
109/L with 87% lymphocytes, a hemoglobin level of 4.9 g/dL,
mean corpuscular volume of 74 fl, and a platelet count
of 73×109/L. The erythrocyte sedimentation rate was 104
mm/hr. The ferritin level was extremely high (2250 ng/mL;
normal range is 12 - 142 for children). Venous blood gas
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Table 1. Genetic and Acquired Causes of Fanconi Syndrome (4)
Primary MissenseMutation of NaPi-II
Cotransporter
Secondary to inherited systemic
diseases
Cystinosis
Tyrosinemia
Hereditary fructose intolerance
Galactosemia
Glycogen storage disease (type I)
Mitochondrial disorders
Wilson’s disease
Lowe’s syndrome
Den’s disease
Fanconi-Bickel syndrome
Acquired
Drugs (tenofovir, ifosfamide,
cisplatin, valproic acid,
aminoglycosides, cidofovir)
Heavy metals
Multiple myeloma
Amyloidosis
Vitamin D deficiency
Renal transplantation
Paroxysmal nocturnal
hemoglobinuria
analysis (ABL 735; Radiometer, Copenhagen, Denmark) was
as follows: pH 7.30, pCO2 29 mmHg, HCO3 13 Meq/L, BE 10
Meq. Liver function tests, thyroid function tests, and evalu-
ation for celiac disease by tissue transglutaminase IgA an-
tibody (TTG IgA) were normal. The results of biochemical
testing (Hitachi 917, Hitachi, Japan) are summarized in Ta-
ble 2.
Immunologic analysis revealed a low IgG level (6 g/L,
normal 6.46 - 14.51) but high IgM (2.7 g/L, normal 0.55 - 2.32)
and IgA (2.3 g/L, normal 0.28 - 2.22). C-reactive protein was
3+ on the latex agglutination test. Urine analysis showed
glucosuria and proteinuria, with a pH of 5. According to
the physical examination results, clinical manifestations,
radiologic findings, and laboratory results, FS was diag-
nosed. On microscopic examination of the bone marrow
aspirate (BMA), two different populations of blasts were
observed (Figure 1). Subsequent flow cytometric analysis
(Partec, CyFlow® Space) revealed 98% blasts with positiv-
ity for CD2, cytoplasmic CD3, CD7, TdT, CD13, CD34, CD117,
and myeloperoxidase. Common chromosomal transloca-
Table 2. Biochemical Test Results for the Patient
Test Result Normal Values Low/Normal or
High According to
Normal Values
Blood sugar (BS) 91 mg/dL 70 - 110 mg/dL Normal
Blood urea
nitrogen (BUN)
9 mg/dL 7 - 18 mg/dL Normal
Serum creatinine
(Cr)
0.7 mg/dL 0.6 - 1.2 mg/dL Normal
Sodium (Na) 137 mEq/L 135 - 145 mEq/L Normal
Potassium (K) 3.3 mEq/L 3.5 - 5.0 mEq/L Low
Calcium (Ca) 8.7 mg/dL 8.4 - 10.2 mg/dL Normal
Uric acid 1.7 mg/dL 3.0 - 8.2 mg/dL Low
Lactate
dehydrogenase
(LDH)
463 U/L 45 - 90 U/L High
Phosphorus (P) 1.1 mg/dL 3.0 - 4.5 mg/dL Low
tions of acute leukemia, including t(4,11), t(12,21), t(1,19),
and t(9,22) by the PCR method were all negative. Accord-
ing to the world health organization (WHO) 2008 classifi-
cation (6), these findings are indicative of a bilineal acute
leukemia with myeloid and T-lymphoid lineages.
Figure 1. Bone Marrow Aspiration Showing Two Different Populations of Blasts
Cerebrospinal fluid analysis and cytology was normal.
The patient received Joulie’s solution for the FS, and a com-
bined chemotherapy regimen that was effective for both
acute myeloid leukemia (AML) and acute lymphoblastic
leukemia (ALL) (modified by the St. Jude XIII-B high risk
protocol) (7). Despite supportive treatments and admin-
istration of wide spectrum antibiotics, the patient died at
the end of the induction phase of chemotherapy due to
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sepsis and disseminated intravascular coagulation (DIC).
Further examinations of family members revealed that the
patient’s 4-year-old sister was similarly diagnosed with FS.
The third child of this family, a newborn baby, was not in-
vestigated.
3. Discussion
Given that dysglobulinemia is a feature of FS, it may
be commonly associated with myeloma, amyloidosis, and
Bence-Jones proteinuria (5). Ma et al. suggested acquired
FS as a complication of monoclonal gammopathy in adults
(8). Messiaen et al. reported several cases of multiple
myeloma that subsequently developed FS (9). Rochman et
al. reported a case of FS as the result of chronic lymphocytic
leukemia (10). There is also a study by Bridoux et al. report-
ing the development of FS in a patient with Waldenström’s
macroglobulinemia (11). The authors suggested that the ac-
cumulation of kappa light chains may have played a signif-
icant role in the development of FS in the reported patients
(9, 11). Another study reported a case with chronic myel-
ogenic leukemia, who developed partial FS after receiving
imatinib mesylate (Gleevec) (12).
Considering the familial occurrence and the child-
hood onset of FS in our patient, an inherited background is
probable. The unusual event in our patient is the develop-
ment of an almost rare acute leukemia, a condition which
has not been reported before.
Although the majority of acute leukemias can be clas-
sified as myeloid, B lymphoid, or T lymphoid lineages
through morphology, immunophenotyping, cytogenetic,
and molecular analyses, there are also rare cases that man-
ifest the characteristics of at least two lineages and ac-
count for 2% - 5% of all acute leukemias (13). Generally,
two main types can be located in this group: bipheno-
typic leukemia and bilineal leukemia. The former refers to
leukemias in which divergent features present in a single
blast population, while the latter describes leukemias with
two different populations of blasts (14). In the WHO 2008
classification, both types are termed as mixed-phenotype
acute leukemia (MPAL) (6). The lineage-specific markers
suggested by the WHO 2008 are listed in Table 3. Accord-
ingly, positivity of myeloperoxidase and cytoplasmic CD3
in either a single or distinct population of blasts (as was
found in our patient) are sufficient for a diagnosis of MPAL
with T/myeloid differentiation. In this classification, MPAL
with BCR-ABL1 fusion or MLL gene rearrangements with the
most common partner gene, AF4 at the 4q21 location, have
been regarded as separate entities (6).
In our patient, there was no evidence of
t(9,22)(q34;q11), which leads to BCR-ABL1 fusion, or of
t(4,11)(q21;q23), which most commonly involves the MLL
gene. Meeting the WHO 2008 criteria, MPAL T/myeloid, not
otherwise specified was the diagnosis in our patient.
Table 3. WHO 2008 Classification of Mixed-Phenotype Acute Leukemias (6)
Lineage Markers
Myeloid Myeloperoxidase Or Monocytic differentiation (at least two of
the following: non-specific esterase, CD11c, CD14, CD64,
lysozyme)
T lymphoid Cytoplasmic CD3 or Surface CD3
B lymphoid Strong CD19 and at least one of the following with strong
expression: CD79a, cytoplasmic CD22, or CD10 or Weak CD19
and at least two of the following with strong expression:
CD79a, cytoplasmic CD22, or CD10
Like other acute leukemias, the clinical presentations
of MPAL are mainly a result of BM failure, and according to
the literature, these include fatigue, infections, and bleed-
ing disorders (6). Hepatosplenomegaly, thrombocytope-
nia, and severe anemia with high levels of ferritin in our
patient were supportive of BM failure, but no bleeding ten-
dency was found. According to the published studies, the
outcome of MPAL is generally poor (15). The study by Lee et
al. indicated that patients with myeloid/T-lymphoid have
an even lower chance of survival than patients affected by
the rest of the MPALs (16). Currently, there is no agreement
on the treatment of MPAL patients, but a chemotherapy
regimen effective for both AML and ALL has been suggested
(6). However, Killick et al. noted that such a therapeutic
protocol is associated with a high rate of early death in
these patients (17). Consistent with the therapeutic strat-
egy elected for in the study by Al-Seraihy et al. we chose the
modified St. Jude XIII-B high-risk protocol for our patient,
since they suggested that this type of therapy is effective at
gaining and maintaining complete remission (18).
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